Chronic Lymphocytic Leukemia | Specialty

Dr. Barrientos on the Role of Acalabrutinib in CLL

January 26th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the role of acalabrutinib (Calquence) for patients with chronic lymphocytic leukemia (CLL).

Dr. Davids on Results of Obinutuzumab With Ibrutinib in CLL

January 25th 2018

Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia (CLL), discusses the initial results of a phase Ib study of ibrutinib (Imbruvica) in combination with obinutuzumab (Gazyva) in patients with relapsed or refractory CLL.

Dr. Rogers on Determining Patients With High-Risk CLL

January 18th 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses how to determine patients with high-risk chronic lymphocytic leukemia (CLL).

Dr. Jain on the Combination of Venetoclax and Ibrutinib in CLL

January 12th 2018

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).

The Role of Transplant and Future of CLL

January 12th 2018

Other Promising Strategies in CLL

January 12th 2018

The Use of Novel PI3K Inhibitors in CLL

January 12th 2018

Combination Therapies in CLL

January 12th 2018

Additional Therapies for R/R CLL

January 12th 2018

Therapeutic Approaches for R/R CLL

January 12th 2018

Maintenance and Frontline Therapy in CLL

January 12th 2018

Managing Patients With CLL

January 12th 2018

Safety and Efficacy of CLL Treatments

January 12th 2018

Therapeutic Approaches for CLL

January 12th 2018

Deciding on CLL Therapy and When to Treat

January 12th 2018

CLL: The Risk of Richter's Transformation

January 12th 2018

The Risk-Stratifying Factors in CLL

January 12th 2018

Combination Therapies Poised to Improve CLL Treatment Landscape

January 8th 2018

Aaron Logan, MD, PhD, discusses the most promising combinations and available treatments for patients with chronic lymphocytic leukemia.

Dr. Flinn on Next Steps With Venetoclax Plus Obinutuzumab in CLL

January 6th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Venetoclax Demonstrates Strong Activity in CLL After BCR Inhibitor

January 4th 2018

Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).